Faeth TherapeuticsFTH
13F holders, Q2 2025 (June 30)10holders +9
0new positions
1sold out
$8.58avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding Faeth Therapeutics Inc. (FTH) in their 13F filings, up 9 from Q1 2025. 0 opened new positions and 1 sold out. The largest holders were Vanguard Group Inc. ($250K), Ikarian Capital, LLC ($193K) and Catalio Capital Management, LP ($126K).
- Company
- Faeth Therapeutics Inc.
- Filed as
- SENSEI BIOTHERAPEUTICS INC (Q2 2025)
- CUSIP
- 81728A207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $7K |
All 13F filers, Q1 2025 → Q2 2025: 734 shares bought and 17,157 shares sold, net −16,423 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Vanguard Group Inc. | 0.00% | Reduce -0.6% | 29,090 | $250K |
| Ikarian Capital, LLC | 0.06% | No change | 22,497 | $193K |
| Catalio Capital Management, LP | 0.03% | No change | 14,718 | $126K |
| UBS Group AG | 0.00% | Add +0.6% | 2,140 | $18K |
| Raymond James Financial Inc. | 0.00% | No change | 700 | $6K |
| Bank of America Corp. | 0.00% | Add +8111.3% | 583 | $5K |
| SBI Securities Co., Ltd. | 0.00% | Add +3139.1% | 149 | $1K |
| JPMorgan Chase & Co. | 0.00% | Reduce -8.8% | 32 | $275 |
| Morgan Stanley | 0.00% | Reduce -97.8% | 10 | $86 |
| BNP Paribas Financial Markets | 0.00% | Add +12.5% | 9 | $77 |
"% of holder's portfolio" is FTH's weight in each manager's 13F, not the share of Faeth Therapeutics Inc. the manager owns.